818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study

Autor:	Okamoto, A., Fleming, G., Bookman, M., Brady, M.F., Swisher, E.M., Steffensen, K.D., Cloven, N.G., Enomoto, T., O'Malley, D.M., Van Le, L., Tewari, K.S., Barlin, J.N., Bradley, W., Moore, K.N., Chan, J., Wu, M., Hashiba, H., Dinh, M.H., Coleman, R.L., Aghajanian, C.
Zdroj:	In Annals of Oncology September 2020 31 Supplement 4:S618-S618
Databáze:	ScienceDirect
Externí odkaz: